GPR183 antagonist-2 can be used for the research of autoimmune diseases; it significantly reduces paw and joint swelling and the gene expression of pro-inflammatory cytokines (MCP-1, MMPs, and VEGF) in a collagen-induced arthritis (CIA) mouse model in a dose-dependent manner.